RNF123 and pancreatic neoplasm: Still, because the same combinatorial approach did not lead to similar outcomes in the poorly immunogenic mouse KPC1 pancreatic cancer model, these researches also suggested that combining anti-TGF-β therapies with immune checkpoint inhibitors may be beneficial only for certain types of cancer, highlighting the relevance of an appropriate selection of patients to undergo this therapeutic strategy.